证券代码：603566 证券简称：普莱柯 公告编号：2025-034 普莱柯生物工程股份有限公司 二、董事会会议审议情况 具体内容详见上海证券交易所网站（www.sse.com.cn）相关公告。 本议案已经公司第五届董事会审计委员会第十四次会议审议通过，同意提交 董事会审议。 表决结果：9 票赞成，0 票反对，0 票弃权。 为提高公司暂时闲置募集资金使用效率，在确保募集资金投资项目建设正常 开展、募集资金安全的前提下，公司拟对额度不超过人民币 2.1 亿元的暂时闲置 募集资金进行现金管理，投资产品为安全性高、流动性好的保本型理财产品。本 议案已经公司第五届董事会审计委员会第十四次会议审议通过，同意提交董事会 审议。 具体内容详见上海证券交易所网站（www.sse.com.cn）相关公告。 表决结果：9 票赞成，0 票反对，0 票弃权。 关于第五届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 普莱柯生物工程股份有限公司（以下简称"公司"）第五届董事会第十九次 会议于 2025 ...

Meeting Overview - The fifth meeting of the Supervisory Board of the company was held on August 28, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Financial Reporting - The 2025 semi-annual report was approved, confirming that its content and format comply with the regulations of the China Securities Regulatory Commission and the stock exchange, accurately reflecting the company's operational results and financial status [1][2]. - The report disclosed no false records, misleading statements, or significant omissions, and no violations of confidentiality by the personnel involved in its preparation were found [1]. Fund Management - The company confirmed that the use of raised funds complies with relevant regulations, with no changes in the purpose of the funds or harm to shareholder interests [2]. - The profit distribution plan for 2025 was deemed compliant and reasonable, ensuring the company's sustainable development while sharing profits with shareholders [2]. - The Supervisory Board approved the temporary use of up to 210 million yuan of idle raised funds for cash management, ensuring it would not affect normal business operations [3]. - Additionally, the company approved the use of 250 million yuan of idle self-owned funds for cash management under necessary approval procedures [3]. Related Transactions - The wholly-owned subsidiary, Luoyang Lepet Health Technology Co., Ltd., plans to acquire four "Meng Tuan" trademarks from Century Mengbang (Shanghai) Information Technology Co., Ltd. for 10,000 yuan, which aligns with the company's pet business development strategy and enhances brand competitiveness [4].

证券代码：603566 证券简称：普莱柯 公告编号：2025-033 至2025 年 9 月 16 日 普莱柯生物工程股份有限公司 关于召开2025年第一次临时股东大会的通知 召开地点：河南省洛阳市洛龙区政和路 15 号公司二楼会议室 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (五)网络投票的系统、起止日期和投票时间。 重要内容提示： 网络投票系统：上海证券交易所股东大会网络投票系统 召开的日期时间：2025 年 9 月 16 日 14 点 00 分 网络投票起止时间：自2025 年 9 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 ...

Core Viewpoint - The announcement from Pulaike indicates a change in the designated representative for the ongoing supervision of its non-public stock issuance, ensuring continuity in oversight responsibilities [1] Group 1 - Pulaike received a letter from Huatai United Securities regarding the replacement of the designated representative for the ongoing supervision of its non-public stock issuance [1] - Huatai United Securities was the sponsor for Pulaike's non-public stock issuance in 2021, originally appointing Zhen Qing and Zhang Ruosi as the supervising representatives [1] - Due to personal work changes, Zhang Ruosi is unable to continue in the role, and Han Feichong has been appointed to take over the responsibilities [1]

证券代码：603566 证券简称：普莱柯 公告编号：2025-037 普莱柯生物工程股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 普莱柯生物工程股份有限公司（以下简称"公司"）于近日收到华泰联合证 券有限责任公司（以下简称"华泰联合证券"）出具的《关于更换普莱柯生物工 程股份有限公司非公开发行股票持续督导保荐代表人的函》。华泰联合证券作为 公司 2021 年度非公开发行股票的保荐机构，原委派甄清先生和张若思先生作为 持续督导保荐代表人。现张若思先生因个人工作变动，不能继续担任持续督导期 的保荐代表人，为保证公司持续督导工作的有序进行，华泰联合证券现委派韩斐 冲先生（简历详见附件）接替张若思先生担任持续督导保荐代表人，继续履行持 续督导职责。 韩斐冲先生，现任华泰联合证券投资银行业务线总监，保荐代表人。曾参与 完成的项目包括：北玻股份、容百科技、设研院、隆华科技、长青集团、江阴银 行、佳沃股份等再融资项目，电科数字、王府井、天山铝业等重大资产重组项目， 在保荐业务执业过程中严格遵 ...

Market Overview - The animal health sector experienced a decline of 0.5% on August 29, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Individual Stock Performance - The top performer in the animal health sector was Qudongli (code: 838275), with a closing price of 11.87 and an increase of 7.23% [1] - Other notable gainers included Yongshun Biological (code: 839729) with a 1.34% increase and Ruipu Biological (code: 300119) with a 0.81% increase [1] - Conversely, *ST Lvkang (code: 002868) saw a significant decline of 3.24%, closing at 26.32 [2] Trading Volume and Capital Flow - The total net outflow of main funds in the animal health sector was 53.36 million yuan, while retail funds saw a net inflow of 29.48 million yuan [2] - The trading volume for Qudongli was 92,700 hands, with a transaction amount of 108 million yuan [1] Fund Flow Analysis - *ST Lvkang experienced a net outflow of 11.85 million yuan from main funds, representing a 24.27% net share [3] - In contrast, retail funds for *ST Lvkang saw a net inflow of 7.44 million yuan, accounting for 15.25% of its total [3] - Other companies like Shenglian Biological and Zhongmu Co. also faced net outflows from main funds, indicating a trend of capital withdrawal in the sector [3]

Group 1 - The company, Pulaike (SH 603566), held its 19th meeting of the 5th board of directors on August 28, 2025, to review the proposal for the full and summary report of the 2025 semi-annual report [1] - For the year 2024, the company's revenue composition is as follows: veterinary biological products account for 96.44%, functional health products account for 1.79%, income from technology licensing or transfer accounts for 0.94%, and other businesses account for 0.83% [1]

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., has announced the use of part of its idle raised funds for cash management to improve fund efficiency and ensure project safety while increasing investment returns [1][2]. Group 1: Fundraising and Management - The company has raised a total of 897,999,976.34 yuan through a non-public offering of 31,420,573 shares at a price of 28.58 yuan per share, with a net amount of 885,820,523.22 yuan after deducting issuance costs [1]. - As of June 30, 2025, the company has utilized 3,884,676.19 yuan of the raised funds, leaving a balance of 201,103,541.25 yuan [1]. Group 2: Cash Management Details - The investment purpose is to enhance the efficiency of idle raised funds, ensure project construction and fund safety, and increase investment returns [2]. - The investment limit is set at no more than 210 million yuan, allowing for single or cumulative rolling cash management within a one-year period [2]. - The funds will be sourced from temporarily idle raised funds and will be invested in low-risk, high-liquidity financial products such as structured deposits and large-denomination certificates of deposit [2]. Group 3: Decision-Making and Oversight - The investment decision does not require shareholder meeting approval and is authorized to the company's legal representative or their authorized personnel [2]. - The company has implemented several risk control measures, including pre-planning by the finance department, ongoing management, and post-tracking accounting [2]. - The supervisory board and independent directors have the authority to oversee and audit the cash management process, ensuring compliance with necessary legal procedures [3].

Core Viewpoint - The company has approved a plan to use up to 210 million yuan of temporarily idle raised funds for cash management, focusing on low-risk and highly liquid financial products [1] Group 1 - The decision was made during the 19th meeting of the fifth board of directors and the 13th meeting of the fifth supervisory board [1] - The investment will be concentrated in principal-protected financial products such as structured deposits and large-denomination certificates of deposit [1] - The resolution is valid for 12 months, allowing funds to be used on a rolling basis within the approved limit [1] Group 2 - The company emphasizes that the investment risks are controllable, although they may still be affected by market fluctuations [1]

华泰联合证券有限责任公司 关于普莱柯生物工程股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为普莱柯生物工程股份有限公司（以下简称"普莱柯"或"公司"）2021 年 度非公开发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所股票上市规则》《上市公司募集资金监管规则》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》及《上海证券交易所上市公司 自律监管指引第 11 号——持续督导》等相关法律法规的规定，对普莱柯本次使 用部分闲置募集资金进行现金管理事项进行了审慎核查，具体核查情况如下： 一、使用闲置募集资金进行现金管理基本情况 （一）募集资金的基本情况 经中国证券监督管理委员会《关于核准普莱柯生物工程股份有限公司非公开 发行股票的批复》（证监许可〔2022〕1251 号）核准，普莱柯生物工程股份有 限公司（以下简称"公司"）非公开发行 31,420,573 股的人民币普通股（A 股）， 发行价格为 28.58 元/股，募集资金总额为 897,999,976.34 元，扣除发行费用后募 集资 ...